The overall effectiveness of a targeted supplement of botanicals, isoflavones, vitamins and minerals on perimenopausal and postmenopausal women and the most common symptoms.

For peri and postmenopausal women does the blind use of the PeriMenoFriend supplement formula compared to a placebo improve their menopause experience and menopause symptoms.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN38087930

Enrollment

300

Registered

2025-02-04

Start date

2024-12-10

Completion date

Unknown

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopause, postmenopause Urological and Genital Diseases

Interventions

This is a double-blind placebo-controlled interventional study of perimenopausal and postmenopausal women taking a food supplement formula versus a placebo, assessing self-reported changes in wellbein

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Experiencing at least one symptom of menopause 2. Perimenopausal Women (have had a period in the last 12 months and are of menopausal age) 3. Postmenopausal Women (have been 12 consecutive months without a period and are of menopausal age)

Exclusion criteria

Exclusion criteria: 1. Have had or are at risk of oestrogen-positive breast cancer 2. Pregnancy or breastfeeding 3. Taking the combined contraceptive pill (containing oestrogen and progesterone) 4. Taking any of these medications: Tamoxifen, Methotrexate, Levodopa, Carbidopa, Warfarin, Benzodiazepines eg Diazepam (Valium) and Clonazepam (Klonopin), Antidepressants. 5. Taking any medications or under medical supervision, please consult a doctor or healthcare professional before joining this study if you are chosen 6. Taking any supplements for menopause and associated symptoms

Design outcomes

Primary

Measure	Time frame
The overall effectiveness of PeriMenoFriend for menopause symptoms and wellbeing over the previous 5 days (if participants feel a difference in menopause symptoms; if participants feel better in themselves) will be measured using self-assessed questionnaires on Days 0, 14, 30, 60 and 90	—

Secondary

Measure	Time frame
The following secondary outcome measures will assess self-reported changes in symptoms and variances between perimenopausal and post-menopausal women using self-assessed questionnaires on Days 0, 14, 30, 60 and 90: 1. The overall effectiveness of PeriMenoFriend for menopause symptoms and wellbeing over the previous 5 days in perimenopausal women 2. The overall effectiveness of PeriMenoFriend for menopause symptoms and wellbeing over the previous 5 days in postmenopausal women	—

Measure

Time frame

The following secondary outcome measures will assess self-reported changes in symptoms and variances between perimenopausal and post-menopausal women using self-assessed questionnaires on Days 0, 14, 30, 60 and 90: 1. The overall effectiveness of PeriMenoFriend for menopause symptoms and wellbeing over the previous 5 days in perimenopausal women 2. The overall effectiveness of PeriMenoFriend for menopause symptoms and wellbeing over the previous 5 days in postmenopausal women

—

Countries

England, United Kingdom

Contacts

Public ContactGordon Lott

gordon@drvegan.com-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 22, 2026